PharmaCorp RX Secures C$10M Bought-Deal Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
- Financing Scale: PharmaCorp RX has entered into a bought-deal agreement to issue 19.6 million units at C$0.51 each, raising gross proceeds of C$10 million, which will enhance the company's liquidity and expansion capabilities.
- Underwriting Syndicate: Acumen Capital Finance Partners and Canaccord Genuity are co-leading the underwriting, reflecting market confidence in PharmaCorp RX's growth potential and increasing investor interest in the company.
- Warrant Structure: Each unit includes one common share and one-half of a warrant, allowing holders to purchase common shares at C$0.60 for up to 24 months, thereby incentivizing investor participation in the company's long-term growth.
- Use of Proceeds: The net proceeds from this offering will be used to fund future acquisition opportunities and general working capital requirements, indicating the company's strategic focus on business expansion and enhancing market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PCRX
Wall Street analysts forecast PCRX stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 25.820
Low
23.00
Averages
30.33
High
38.00
Current: 25.820
Low
23.00
Averages
30.33
High
38.00
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PharmaCorp RX Secures C$10M Bought-Deal Agreement
- Financing Scale: PharmaCorp RX has entered into a bought-deal agreement to issue 19.6 million units at C$0.51 each, raising gross proceeds of C$10 million, which will enhance the company's liquidity and expansion capabilities.
- Underwriting Syndicate: Acumen Capital Finance Partners and Canaccord Genuity are co-leading the underwriting, reflecting market confidence in PharmaCorp RX's growth potential and increasing investor interest in the company.
- Warrant Structure: Each unit includes one common share and one-half of a warrant, allowing holders to purchase common shares at C$0.60 for up to 24 months, thereby incentivizing investor participation in the company's long-term growth.
- Use of Proceeds: The net proceeds from this offering will be used to fund future acquisition opportunities and general working capital requirements, indicating the company's strategic focus on business expansion and enhancing market competitiveness.
See More
Semiconductor Stocks Surge; Watts Water Upgraded
- Semiconductor ETF Performance: The VanEck Semiconductor ETF (SMH) is on track for a 70% surge in Q2, driving chip stocks higher, with Astera Labs up 7%, KLA Corp up 8%, and Applied Materials up 5%, indicating strong market confidence in the semiconductor sector.
- Watts Water Upgrade: Watts Water Technologies jumped over 7% after Barclays upgraded its rating to overweight, as the company is seen as best positioned to benefit from the data center capital expenditures cycle with its expanding portfolio in waste and water technology.
- Abivax Stock Surge: U.S.-traded shares of French biotech company Abivax soared 40% after releasing new data on its ulcerative colitis treatment, showing malignancy rates in line with expectations and over 37% of initially non-responsive patients achieving clinical remission after about 10 months, highlighting treatment efficacy.
- Air Products Project Cancellation: Air Products and Chemicals rose over 8% after announcing it would not proceed with its Louisiana Clean Energy Complex, which is expected to incur up to $2.9 billion in pretax charges, reflecting the company's stringent financial return criteria.
See More
Pacira BioSciences Divests iovera° Business to Zimmer Biomet for Up to $140M
- Transaction Value: Pacira BioSciences is divesting its iovera° business to Zimmer Biomet for up to $140 million, including a $70 million upfront payment and additional revenue-based milestone payments, reflecting the market value and future potential of the business.
- Technology Overview: iovera° is an innovative, FDA-cleared, drug-free medical device that relieves pain through cryoneurolysis, applying focused cold therapy to a targeted nerve to temporarily interrupt its ability to transmit pain signals, highlighting its uniqueness in pain management.
- Use of Proceeds: Pacira plans to use the proceeds from this transaction to strengthen its balance sheet, indicating a strategic intent to optimize financial structure and enhance future investment capabilities.
- Closing Timeline: The transaction is slated to close in Q3, marking a significant step in Pacira's business restructuring and strategic focus, potentially laying the groundwork for its subsequent development.
See More
Pacira Divests iovera Business to Zimmer Biomet for Up to $140 Million
- Transaction Amount and Structure: Pacira BioSciences has agreed to divest its iovera business to Zimmer Biomet for up to $140 million, which includes a $70 million upfront payment and an additional $70 million in milestone payments through December 31, 2031, reflecting confidence in future revenue potential from both parties.
- Timeline for Completion: The transaction is expected to close in the third quarter of 2026, providing ample time for both companies to integrate resources and plan for subsequent business developments.
- Strategic Collaboration Outlook: The companies will also collaborate on advancing the spasticity program, with Pacira eligible for additional compensation upon successful completion of the registrational study and regulatory approval, which not only strengthens their partnership but also provides Pacira with a potential revenue stream.
- Financial Impact: Pacira intends to use the net proceeds from this transaction to strengthen its balance sheet, including repaying its senior secured revolving credit facility, a move that will help improve the company's financial health.
See More
Pacira Partners with Zimmer Biomet for $140 Million Deal
- Significant Transaction Value: Pacira's deal with Zimmer Biomet totals up to $140 million, including an upfront payment of $70 million and potential future revenue-based milestone payments, which is expected to enhance Pacira's financial position and support its transition into an innovative biopharmaceutical company.
- Strategic Collaboration Advancement: The two companies will collaborate on advancing the spasticity program, with Pacira having the opportunity for additional compensation upon successful completion of the registrational study, which not only accelerates the development of new therapies but also enhances the company's competitiveness in the non-opioid market.
- Technology Transfer Assurance: Upon closing, Zimmer Biomet will obtain all rights for the development, manufacturing, and commercialization of iovera°, and Pacira will ensure a smooth transition through a customary transition services agreement, thereby reducing operational risks and optimizing resource allocation.
- Positive Future Outlook: The transaction is expected to close in the third quarter of 2026 and aligns with Pacira's 5x30 strategy, demonstrating the company's commitment to achieving long-term growth through innovation and collaboration, further solidifying its leadership position in pain management.
See More
Pacira BioSciences Announces Board Election Results
- Board Election Results: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected to the Board, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to executing the 5x30 strategy to drive long-term value and maintain positive momentum moving forward.
- Independent Election Oversight: The election results will be finalized and certified by an independent inspector of elections, with a report to be filed on Form 8-K with the SEC, ensuring transparency and compliance.
- Innovative Pain Therapies: Pacira focuses on non-opioid pain management with three commercial products, including EXPAREL, ZILRETTA, and iovera, aiming to enhance patient quality of life and expand market share.
See More
PharmaCorp RX Secures C$10M Bought-Deal Agreement
- Financing Scale: PharmaCorp RX has entered into a bought-deal agreement to issue 19.6 million units at C$0.51 each, raising gross proceeds of C$10 million, which will enhance the company's liquidity and expansion capabilities.
- Underwriting Syndicate: Acumen Capital Finance Partners and Canaccord Genuity are co-leading the underwriting, reflecting market confidence in PharmaCorp RX's growth potential and increasing investor interest in the company.
- Warrant Structure: Each unit includes one common share and one-half of a warrant, allowing holders to purchase common shares at C$0.60 for up to 24 months, thereby incentivizing investor participation in the company's long-term growth.
- Use of Proceeds: The net proceeds from this offering will be used to fund future acquisition opportunities and general working capital requirements, indicating the company's strategic focus on business expansion and enhancing market competitiveness.
See More
Semiconductor Stocks Surge; Watts Water Upgraded
- Semiconductor ETF Performance: The VanEck Semiconductor ETF (SMH) is on track for a 70% surge in Q2, driving chip stocks higher, with Astera Labs up 7%, KLA Corp up 8%, and Applied Materials up 5%, indicating strong market confidence in the semiconductor sector.
- Watts Water Upgrade: Watts Water Technologies jumped over 7% after Barclays upgraded its rating to overweight, as the company is seen as best positioned to benefit from the data center capital expenditures cycle with its expanding portfolio in waste and water technology.
- Abivax Stock Surge: U.S.-traded shares of French biotech company Abivax soared 40% after releasing new data on its ulcerative colitis treatment, showing malignancy rates in line with expectations and over 37% of initially non-responsive patients achieving clinical remission after about 10 months, highlighting treatment efficacy.
- Air Products Project Cancellation: Air Products and Chemicals rose over 8% after announcing it would not proceed with its Louisiana Clean Energy Complex, which is expected to incur up to $2.9 billion in pretax charges, reflecting the company's stringent financial return criteria.
See More
Pacira BioSciences Divests iovera° Business to Zimmer Biomet for Up to $140M
- Transaction Value: Pacira BioSciences is divesting its iovera° business to Zimmer Biomet for up to $140 million, including a $70 million upfront payment and additional revenue-based milestone payments, reflecting the market value and future potential of the business.
- Technology Overview: iovera° is an innovative, FDA-cleared, drug-free medical device that relieves pain through cryoneurolysis, applying focused cold therapy to a targeted nerve to temporarily interrupt its ability to transmit pain signals, highlighting its uniqueness in pain management.
- Use of Proceeds: Pacira plans to use the proceeds from this transaction to strengthen its balance sheet, indicating a strategic intent to optimize financial structure and enhance future investment capabilities.
- Closing Timeline: The transaction is slated to close in Q3, marking a significant step in Pacira's business restructuring and strategic focus, potentially laying the groundwork for its subsequent development.
See More
Pacira Divests iovera Business to Zimmer Biomet for Up to $140 Million
- Transaction Amount and Structure: Pacira BioSciences has agreed to divest its iovera business to Zimmer Biomet for up to $140 million, which includes a $70 million upfront payment and an additional $70 million in milestone payments through December 31, 2031, reflecting confidence in future revenue potential from both parties.
- Timeline for Completion: The transaction is expected to close in the third quarter of 2026, providing ample time for both companies to integrate resources and plan for subsequent business developments.
- Strategic Collaboration Outlook: The companies will also collaborate on advancing the spasticity program, with Pacira eligible for additional compensation upon successful completion of the registrational study and regulatory approval, which not only strengthens their partnership but also provides Pacira with a potential revenue stream.
- Financial Impact: Pacira intends to use the net proceeds from this transaction to strengthen its balance sheet, including repaying its senior secured revolving credit facility, a move that will help improve the company's financial health.
See More
Pacira Partners with Zimmer Biomet for $140 Million Deal
- Significant Transaction Value: Pacira's deal with Zimmer Biomet totals up to $140 million, including an upfront payment of $70 million and potential future revenue-based milestone payments, which is expected to enhance Pacira's financial position and support its transition into an innovative biopharmaceutical company.
- Strategic Collaboration Advancement: The two companies will collaborate on advancing the spasticity program, with Pacira having the opportunity for additional compensation upon successful completion of the registrational study, which not only accelerates the development of new therapies but also enhances the company's competitiveness in the non-opioid market.
- Technology Transfer Assurance: Upon closing, Zimmer Biomet will obtain all rights for the development, manufacturing, and commercialization of iovera°, and Pacira will ensure a smooth transition through a customary transition services agreement, thereby reducing operational risks and optimizing resource allocation.
- Positive Future Outlook: The transaction is expected to close in the third quarter of 2026 and aligns with Pacira's 5x30 strategy, demonstrating the company's commitment to achieving long-term growth through innovation and collaboration, further solidifying its leadership position in pain management.
See More
Pacira BioSciences Announces Board Election Results
- Board Election Results: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected to the Board, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to executing the 5x30 strategy to drive long-term value and maintain positive momentum moving forward.
- Independent Election Oversight: The election results will be finalized and certified by an independent inspector of elections, with a report to be filed on Form 8-K with the SEC, ensuring transparency and compliance.
- Innovative Pain Therapies: Pacira focuses on non-opioid pain management with three commercial products, including EXPAREL, ZILRETTA, and iovera, aiming to enhance patient quality of life and expand market share.
See More
